Substituted aromatic ethers as inhibitors of glycine transport
申请人:Pfizer Inc.
公开号:US20030013887A1
公开(公告)日:2003-01-16
This invention relates to a series of substituted aromatic ethers of the formula I
1
wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.